Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy
An Zhu , Yu Bai , Yanyang Nan , Dianwen Ju
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70046
Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy
•Innovative NKCEs: NK cell engagers (NKCEs) represent a promising new class of immunotherapeutics targeting tumours by activating NK cells. | |
•Multi-specific formats: The transition from bi-specific to multi-specific NKCEs enhances their versatility and therapeutic efficacy. | |
•Mechanisms of action: NKCEs have the potential to improve NK cell activation by engaging activating receptors and incorporating cytokines. | |
•Clinical potential: Current clinical trials demonstrate the safety and efficacy of various NKCEs across different cancer types. | |
•Future research directions: Optimising NKCE designs and exploring combination therapies are essential for overcoming challenges in cancer treatment. |
bi-specific NKCEs / cytokines / natural killer cell engagers / NK receptors / tetra-specific NKCEs / tri-specific NKCEs
2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
